An Analysis of Covid-19 Effect on Patients With Colorectal Cancer - Follow-up Regarding Tumour Stage, Neoadjuvant Treatment, Delay and Long-term Survival
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 8,000
- 试验地点
- 1
- 主要终点
- Yearly incidence of rectal cancer
研究概览
简要总结
Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown.
The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Rectal cancer diagnosis 2019-2022
排除标准
- •No rectal cancer diagnosis 2019-2022
结局指标
主要结局
Yearly incidence of rectal cancer
时间窗: 2019-2022
The number of patients diagnosed yearly 2019, 2020, 2021 and 2022
次要结局
- Patient's delay(12 months prior diagnosis)
- Symptoms at diagnosis(6 months prior diagnosis)
- Doctor's delay(12 months prior diagnosis)
- Treatment changes(Diagnosis and 12 months following)
研究者
Eva Angenete
Professor
Sahlgrenska University Hospital, Sweden